Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study

被引:30
作者
Rotondo, Cinzia [1 ]
Cantatore, Francesco Paolo [1 ]
Fornaro, Marco [2 ]
Colia, Ripalta [1 ]
Busto, Giuseppe [1 ]
Rella, Valeria [1 ]
Sciacca, Stefania [1 ]
Lops, Lucia [1 ]
Cici, Daniela [1 ]
Maruotti, Nicola [1 ]
D'Onofrio, Francesca [1 ]
Iannone, Florenzo [2 ]
Corrado, Addolorata [1 ]
机构
[1] Osped Riuniti Foggia, Rheumatol Unit, Dept Med & Surg Sci, Viale Luigi Pinto 1, I-71122 Foggia, Italy
[2] Policlinico, Rheumatol Unit, Dept Emergency & Organ Transplantat, Piazza G Cesare 11, I-70124 Bari, Italy
关键词
rheumatic diseases; relapse; flare; disease activity; DMARDs; biologic drugs; safety; efficacy; anti-COVID-19; vaccine; comirnaty; vaxzevria; SARs-COV-2; INFECTIONS; VACCINATION; RISK;
D O I
10.3390/vaccines9070730
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
An increased risk of developing severe infections has been evidenced in rheumatic disease (RD) patients, and anti-COVID-19 vaccination is strictly recommended for RD patients. However, up to now, no data are available on safety, immunogenicity and efficacy of COVID-19 vaccinations in RD patients. The possible development of adverse events (AEs), including the flare-up of underlying RD, represents a matter of growing importance. The aim of our study is to assess, in RD patients, the safety profile of different types of approved vaccines and the possible influence of immunosuppressive therapies and clinical or demographic characteristics of RD patients on development of AEs. Participants (n = 185; 30.7%) received anti-COVID-19 vaccinations, 137 with autoimmune/chronic inflammatory RD (Au/cIn-RD) and 48 with nonautoimmune/chronic inflammatory RD (no-Au/cIn-RD). AEs were recorded in 42% of patients after the first dose of vaccine, and in 26% of patients after the second dose. The most common reported AEs after anti-COVID 19 vaccines were site injection pain (17%), headache (12%), fever (12%), myalgia (10%) and fatigue (10%). Relapses of the underlying Au/c-In-RD were recorded in 2.2% of patients after the first dose of vaccine. In Au/c-In-RD the risk of developing AEs after the first dose of vaccine was lower in older patients (OR = 0.95; p = 0.001), and in the group of patients with complete control of RD (OR: 0.2; p = 0.010). A lower percentage of AEs was observed in patients with complete control of their Au/cIn-RD (29%) compared to those with low (57%) or moderate-high disease activity (63%) (p = 0.002 and p = 0.006 respectively). In this study all types of COVID-19 vaccines in use in Italy seemed safe in RD patients. The results of this study might provide reassuring information for Au/cIn RD patients and clinicians and could strengthen the data on vaccine safety to guide the use of COVID-19 vaccines in Au/cIn-RD on immunosuppressive agents.
引用
收藏
页数:11
相关论文
共 26 条
[1]   Immunosuppressive drugs, the first 50 years and a glance forward [J].
Allison, AC .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :63-83
[2]  
[Anonymous], 2020, PLoS medicine, DOI DOI 10.1371/JOURNAL.PMED.1003166
[3]   Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis [J].
Bernatsky, S. ;
Hudson, M. ;
Suissa, S. .
RHEUMATOLOGY, 2007, 46 (07) :1157-1160
[4]   Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases [J].
Buehler, Silja ;
Eperon, Gilles ;
Ribi, Camillo ;
Kyburz, Diego ;
van Gompel, Fons ;
Visser, Leo G. ;
Siegrist, Claire-Anne ;
Hatz, Christoph .
SWISS MEDICAL WEEKLY, 2015, 145
[5]   VALIDATION OF A COMBINED COMORBIDITY INDEX [J].
CHARLSON, M ;
SZATROWSKI, TP ;
PETERSON, J ;
GOLD, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (11) :1245-1251
[6]   Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders [J].
Chau, Charlene Y. C. ;
Chow, Loraine L. W. ;
Sridhar, Siddharth ;
Shih, Kendrick C. .
OPHTHALMOLOGY AND THERAPY, 2021, 10 (02) :201-209
[7]   Influenza Vaccination Responses in Human Systemic Lupus Erythematosus Impact of Clinical and Demographic Features [J].
Crowe, Sherry R. ;
Merrill, Joan T. ;
Vista, Evan S. ;
Dedeke, Amy B. ;
Thompson, David M. ;
Stewart, Scott ;
Guthridge, Joel M. ;
Niewold, Timothy B. ;
Franek, Beverly S. ;
Air, Gillian M. ;
Thompson, Linda F. ;
James, Judith A. .
ARTHRITIS AND RHEUMATISM, 2011, 63 (08) :2396-2406
[8]   Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists [J].
Curtis, Jeffrey R. ;
Patkar, Nivedita ;
Xie, Aiyuan ;
Martin, Carolyn ;
Allison, Jeroan J. ;
Saag, Michael ;
Shatin, Deborah ;
Saag, Kenneth G. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (04) :1125-1133
[9]   American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1 [J].
Curtis, Jeffrey R. ;
Johnson, Sindhu R. ;
Anthony, Donald D. ;
Arasaratnam, Reuben J. ;
Baden, Lindsey R. ;
Bass, Anne R. ;
Calabrese, Cassandra ;
Gravallese, Ellen M. ;
Harpaz, Rafael ;
Sadun, Rebecca E. ;
Turner, Amy S. ;
Williams, Eleanor Anderson ;
Mikuls, Ted R. .
ARTHRITIS & RHEUMATOLOGY, 2021, 73 (07) :1093-1107
[10]   Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study [J].
Doran, MF ;
Crowson, CS ;
Pond, GR ;
O'Fallon, WM ;
Gabriel, SE .
ARTHRITIS AND RHEUMATISM, 2002, 46 (09) :2287-2293